classic choroidal neovascularization

classic choroidal neovascularization

well-demarcated areas of hyperfluorescence observed in the early phases of a retinal angiogram.

clas·sic cho·roi·dal neo·vas·cu·la·ri·za·tion

(klas'ik kōr-oy'dăl nē-ō-vas'kyū-lar-ī-zā'shŭn)
Well-demarcated areas of hyperfluorescence observed in the early phases of a retinal angiogram; caused by blood vessels from the choroid breakup in the subretinal space.
References in periodicals archive ?
Two important trials--the MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD) and ANCHOR (Anti-VEGF Antibody Ranibizumab for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD)--showed the beneficial effect of Lucentis for neovascular AMD, regardless of lesion subtype.
ANCHOR (ANti-VEGF Antibody for the Treatment of Predominantly Classic CHORoidal Neovascularization in AMD) is a Phase III randomized, multi-center, double-masked, active-treatment controlled study comparing two different doses of LUCENTIS to verteporfin (Visudyne(R)) photodynamic therapy (PDT) in 423 patients with predominantly classic wet AMD in the United States, Europe and Australia.
MARINA (Minimally Classic/OccultTrial of the Anti-Vascular Endothelial Growth Factor Antibody Ranibizumab in the Treatment of Neovascular Endothelial Age-Related Macular Degeneration) and ANCHOR (Anti-VEGF antibody for the treatment of predominantly classic Choroidal Neovascularization in Age-Related Macular Degeneration) evaluated drugs including Lucentis, for treatment of age-related and other forms of macular degeneration (AMD).
The MARINA study enrolled patients with occult and minimally classic choroidal neovascularization (CNV), the form of CNV found in most patients with wet AMD, while the ANCHOR study enrolled patients with predominantly classic CNV.
ANCHOR (ANti-VEGF Antibody for the Treatment of Predominantly Classic CHORoidal Neovascularization in AMD) is a Phase III randomized, two-year, multi-center, double-masked, active-treatment controlled study comparing two different doses of Lucentis to PDT in 423 patients with predominantly classic wet AMD.
In November 2005, Genentech announced positive preliminary data from the pivotal Phase III ANCHOR study (ANti-VEGF Antibody for the Treatment of Predominantly Classic CHORoidal Neovascularization in AMD), a randomized, two-year, multi-center, double-masked, active-treatment controlled study comparing two different doses of Lucentis to PDT in 423 patients with predominantly classic wet AMD.
The VIO trial was a Phase III, multi-center double-masked randomized trial to determine if photodynamic therapy with Visudyne can reduce the risk of vision loss in wet age-related macular degeneration (AMD) patients with subfoveal occult with no classic choroidal neovascularization (CNV).
Genentech and Novartis Pharma AG are conducting an additional Phase III study of Lucentis, ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly Classic CHORoidal Neovascularization in AMD).
ANCHOR (ANti-VEGF Antibody for the Treatment of Predominantly Classic CHORoidal Neovascularization in AMD) is a randomized, multi-center, double-masked, active-treatment-controlled Phase III study comparing two different doses of Lucentis to PDT in 423 patients.
The VIO trial is an ongoing Phase III, multicenter double-masked randomized trial to determine if photodynamic therapy with Visudyne can reduce the risk of vision loss in age-related macular degeneration (AMD) patients with subfoveal occult with no classic choroidal neovascularization (CNV).
NASDAQ:QLTI; TSE:QLT) today announced that the American Journal of Ophthalmology, a leading peer-reviewed medical journal, has published favourable two-year results from a phase III clinical trial, showing Visudyne(TM) (verteporfin for injection) therapy has a significant treatment benefit in age-related macular degeneration (AMD) patients presenting with occult without classic choroidal neovascularization (CNV).